

# Clinical trials of Abciximab + reteplase

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 acute myocardial infarction

| Trial   | Treatments   | Patients   | Trials design and methods |
|---|--|--|---------------------------|
| <b>Abciximab + reteplase vs primary intervention</b>  |  |  |                           |
| <b>BRAVE (Kastrati) , 2004</b><br>n=125/128<br>follow-up: 30 days                                       | -  | symptom duration <12h  |                           |
| <b>FINESSE (combination-facilitated PCI) , 2008</b><br>[NCT00046228]<br>n=828/806<br>follow-up: 90 days | combination-facilitated PCI with abciximab plus half-dose reteplase versus primary PCI (abciximab administered immediately before the procedure) | patients with acute ST-segment elevation myocardial infarction; symptom duration <6h | Parallel groups<br>open   |

└ More details and results :

- myocardial revascularization for acute myocardial infarction in facilitated PCI at <http://www.trialresultscenter.org/go-Q90>

## References

### **BRAVE (Kastrati), 2004:**

Kastrati A, Mehilli J, Schlotterbeck K, Dotzer F, Dirschinger J, Schmitt C, Nekolla SG, Seyfarth M, Martinoff S, Markwardt C, Clermont G, Gerbig HW, Leiss J, Schwaiger M, Schmig A Early administration of reteplase plus abciximab vs abciximab alone in patients with acute myocardial infarction referred for percutaneous coronary intervention: a randomized controlled trial. JAMA 2004;291:947-54 [[14982910](#)]

### **FINESSE (combination-facilitated PCI), 2008:**

Ellis SG, Tendera M, de Belder MA, van Boven AJ, Widimsky P, Janssens L, Andersen HR, Betriu A, Savonitto S, Adamus J, Peruga JZ, Kosmider M, Katz O, Neunteufl T, Jorgova J, Dorobantu M, Grinfeld L, Armstrong P, Brodie BR, Herrmann HC, Montalescot G, Neum Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med 2008 May 22;358:2205-17 [[18499565](#)]

Entry terms: abciximab